IGHE and asthma: Among allergies with a mixed (IgE and cell-mediated) pathophysiology, omalizumab could be helpful in improving atopic dermatitis [4] that shares with asthma, inflammatory mediators [5] and the response to allergen immunotherapy [6] but it did not improve eosinophilic esophagitis [2].